title: ECT and TRH: cholinergic involvement in a cognitive deficit state.
abstract: In this paper we describe the findings from two preliminary experiments, a human and an animal study, investigating whether thyrotropin-releasing hormone (TRH) can mitigate electroconvulsive therapy (ECT)-induced cognitive deficits. Our results suggest further explorations of TRH and its analogs as possible therapeutic agents for these deficits. We speculate that the major cause of the ECT-induced cognitive deficits is a decrease in cholinergic transmission in the central nervous system. Treatments such as TRH, which enhance cholinergic activity, can reverse the cognitive deficits.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98195.
authors.forename: A
authors.initials: A
authors.lastname: Khan
authors.forename: M H
authors.initials: MH
authors.lastname: Mirolo
authors.forename: H
authors.initials: H
authors.lastname: Lai
authors.forename: K
authors.initials: K
authors.lastname: Claypoole
authors.forename: L
authors.initials: L
authors.lastname: Bierut
authors.forename: R
authors.initials: R
authors.lastname: Malik
authors.forename: J
authors.initials: J
authors.lastname: Bhang
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D004565:Electroconvulsive Therapy / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D051381:Rats; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D013973:Thyrotropin-Releasing Hormone